Dolutegravir plus lamivudine shows comparable efficacy and safety with standard-of-care three-drug regimen in patients with ...

Any donation you make helps us continue our work towards a world where HIV is no longer a threat to health or happiness. £5 allows us to reach millions of people globally with accurate and reliable ...

Bay Area drug giant Gilead is plotting the trial of a groundbreaking, once-a-year HIV prevention drug lenacapavir.

North America was the major shareholder in 2022. However, Asia-Pacific is expected to witness the highest CAGR during the forecast period. PO ...